Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Core Points - Glancy Prongay & Murray LLP is investigating AVITA Medical, Inc. for potential violations of federal securities laws [1] - AVITA Medical reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of 2025 [2] - The company's stock price dropped by 21%, closing at $4.25 per share following the announcement of the backlog [2] Company Summary - AVITA Medical, Inc. (NASDAQ: RCEL) is facing scrutiny due to a backlog of unpaid claims related to its wound care product, Recell, which has created uncertainty among providers [2] - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims [2] Legal Context - Investors who lost money on AVITA Medical are encouraged to inquire about potential claims to recover losses [2] - The investigation by Glancy Prongay & Murray LLP may lead to legal actions if violations are confirmed [1][2]